Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | PDE8A | O60658 | 10/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22694587 | 0.83 | CDK1 (0.43) | CDK1CCNB1CCNE1CDK2PDE8A | |
| SCHEMBL15354451 | 0.76 | CDK1 (0.73) | CDK1CCNB1CCNE1CDK2PDE8A | |
| SCHEMBL5731732 | 0.75 | PDE4A (0.66) | CDK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22694586 | 0.74 | CDK1 (0.46) | CDK1CCNB1CCNE1CDK2PDE8A | |
| SCHEMBL232387 | 0.74 | ADORA2A (0.62) | CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL14094607 | 0.73 | ADORA2A (0.39) | — | |
| SCHEMBL24338022 | 0.73 | CDK1 (0.50) | CDK1CCNB1CCNE1CDK2PDE8A | |
| SCHEMBL13766331 | 0.73 | CDK1 (0.50) | CDK1CCNB1CCNE1CDK2PDE8A | |
| SCHEMBL179425 | 0.73 | PI4KA (0.63) | CDK1CCNB1CCNE1CDK2PDE8A | |
| SCHEMBL12769342 | 0.71 | ADORA2A (0.49) | CDK1CCNB1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | NLN, NME4, COQ8A | CDK1 2214/4885CCNB1 3687/4885CCNE1 4592/4885 |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, PDF | CDK1 3523/4885CCNB1 3761/4885CCNE1 4627/4885 |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | NLN, NME4, COQ8A | CDK1 2214/4885CCNB1 3687/4885CCNE1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.